

Shields Signature Imaging, LLC
DoN # N/A-24102913-AM

AMENDMENT QUESTIONS #2

Responses should be sent to DoN staff at DPH.DON@State.MA.US

While you may submit each answer as available, please

- List question number and question for each answer you provide
- Submit responses as a separate word document, using the above application title and number as a running header and page numbers in the footer
- When providing the answer to the final question, submit all questions and answers in one final document
- Submit responses in WORD or EXCEL; only use PDF's if absolutely necessary. If "cutting and pasting" charts, provide them in a PDF so they can be clearly seen
- **Whenever possible, include a table with the response**
- **For HIPAA compliance Do not include numbers <11.**

1. In responses to DoN Questions #1 the Holder states, Shields Signature Imaging received DPH approval to temporarily relocate the PETCT service from the hospital campus to another location in Brockton during the hospital's closure (pg.2).

- a. What is the timeline for relocation of the PET/CT unit back to Brockton Hospital?

[It is expected that PETCT will return to Brockton hospital in the second quarter of 2025. The Applicant will work to operationalize the additional day of service upon receipt of regulatory approval.](#)

2. In responses to DoN Questions #1, the Holder states, it is projected that 7- 10 percent of total volume going forward will be attributable to amyloid and FDG PET cases (pg.3).

- a. By how much does the Holder expect the other sources of increasing demand for PET/CT services to contribute to the increase in projected volume?

[Typically FDG tumor imaging grows between 5 and 7% annually and reflects the tumor registry of the cancer center, this figure is separate from the subset of FDG brain scans specifically referenced in association with amyloid brain scans.](#)

[Prostate PSMA imaging will continue to grow in the 7 to 10 % range annually with broader adoption.](#)